The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine

Clinical Pharmacokinetics

Volumn 31, Issue 1, 1996, Pages 29-46

  Perucca, Emilio ^a   Bialer, Meir ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CARBONATE DEHYDRATASE; DIGOXIN; ETHINYLESTRADIOL; ETIRACETAM; FOSPHENYTOIN SODIUM; KAINIC ACID RECEPTOR; LOSIGAMONE; NAPROXEN; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; REMACEMIDE; RUFINAMIDE; SALICYLIC ACID DERIVATIVE; SODIUM CHANNEL BLOCKING AGENT; STIRIPENTOL; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; ZONISAMIDE;

AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TRANSFORMATION; ENZYME INHIBITION; EPILEPSY; GABAERGIC TRANSMISSION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW; URINARY EXCRETION;

EID: 0029887507     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199631010-00003     Document Type: Review

References (120)

1. Richens A, Perucca E. Clinical pharmacology and medical treatment. In: Laidlaw J, Richens A, Chadwick D, editors. A textbook of epilepsy. Edinburgh: Churchill-Livingstone. 1993: 495-559
2. Bialer M. Comparative pharmacokinetics of the newer antiepileptic drugs. Clin Pharmacokinet 1993; 24: 441-52
3. Perucca E. The clinical pharmacology of the new antiepileptic drugs. Pharm Res 1993; 28: 89-106
4. Goa KL, Sorkin EM. Gabapentin: a review of its pharmacological properties and clinical potential in epilepsy. Drugs 1993; 46: 409-27
5. Goa KL, Ross SR, Chrisp P. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993; 46: 152-76
6. Grant SM, Faulds D. Oxcarbazepine: a review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs 1992; 43: 873-88
7. Palmer KJ, McTavish D. Felbamate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy. Drugs 1993; 45: 1041-65
8. Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 1993; 25: 433-43
9. Rev E, Pons G, Olive G. Vigabatrin clinical pharmacokinetics. Clin Pharmacokinet 1992; 23: 267-78
10. Richens A. Clinical pharmacokinetics of gabapentin. In: Chadwick D, editor. New trends in epilepsy management. London: Royal Society of Medicine Services Ltd, 1993: 41-6
11. Maryanoff BE, Margul BL. Topiramate. Drugs Future 1989; 14: 342-4
12. Shank RP. Preclinical profile of topiramate, a novel anticonvulsant. Adv Antiepilep Drug Ther 1995; 1: 1-6
13. Shank RP, Gardocki JF, Vaught JL, et al. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 1994; 35: 450-60
14. Reife RA, Pledger GW. Clinical efficacy of topiramate: US and European experience. Adv Antiepilep Drug Ther 1995; 1: 17-23
15. Easterling DE, Zakszewski T, Mover MD, et al. Plasma pharmacokinetics of topiramate, a new anticonvulsant, in humans [abstract]. Epilepsia 1988; 29: 662
16. Takahashi A, Kasahara T, Sugiyama T, et al. Phase I study of topiramate in Japanese subjects. Epilepsia 1995; 36 Suppl. 3: S149
17. Doose DR, Gisclon LG, Liao S, et al. Pharmacokinetics of topiramate. Adv Antiepilep Drug Ther 1995; 1: 7-16
18. Perucca E. Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs. Epilepsia 1996; 37 Suppl. 2: S8-12
19. Doose DR, Scott VV, Margul BL, et al. Multiple-dose pharmacokinetics of topiramate in healthy male subjects [abstract]. Epilepsia 1988; 29: 662
20. Doose DR, Walker SA, Sachdeo R, et al. Steady-state pharmacokinetics of Tegretol (carbamazepine) and Topamax (topiramate) in patients with epilepsy on monotherapy and during combination therapy [abstract]. Epilepsia 1994; 35 Suppl. 8: 54
21. Gisclon LG, Curtin CR, Kramer LD, et al. Steady-stale pharmacokinetics of phenytoin (Dilantin) and topiramate (Topamax) in epileptic patients on monotherapy and during combination therapy [abstract]. Epilepsia 1994; 35 Suppl. 8: 54
22. Sachdeo RC, Sachdeo SK, Walker SA, et al. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia. In press
23. Holland ML, Evans CR, Lucas PN, et al. The effect of co-administration of probenecid on the pharmacokinetics of topiramate in female Sprague-Dawley rats [abstract no. 195]. 4th North American Meeting ot the International Society for the Study of Xenobiotics: 1992 Nov 2-6: Bar Harbour (FL).
24. Ben-Menachem E. Potential antiepileptic drugs: topiramate. In: Levy RH, Malison RH, Meldrum BS, editors. Antiepileptic drugs. New York: Raven Press, 1995: 1063-70
25. Floren KL, Graves NM, Leppik IE, et al. Pharmacokinetics of topiramate in patients with partial epilepsy receiving phenytoin or valproate [abstract]. Epilepsia 1989; 30: 646
26. Rosenfeld WE, Liao S, Kramer LD, et al. Comparison of the steady-state pharmacokinetics of topiramate and valproic acid in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia. In press
27. Rosenfeld WE, Doose DR, Walker SA, et al. The steady-state pharmacokinetics of topiramate as adjunctive therapy in pediatric subjects with epilepsy. Poster presented at the 21st International Epilepsy Congress: 1995 Sep 3-8: Sydney
28. Reife RA, Pledger G, Doose D, et al. Topiramate: PK/PD analyses [abstract]. Epilepsia 1995; 36 Suppl. 3: S152
29. Doose DR, Walker SA, Pledger G, et al. Evaluation of phenoharbital and primidone/phenoharbital (primidone's active metabolite) plasma concentrations during administration of add-on topiramate therapy in live multicenter, double-blind, placebo controlled trials in outpatients with partial seizures [abstract]. Epilepsia 1995; 36 Suppl. 3: S158
30. Levy RH, Bishop F, Streeter AJ, et al. Explanation and prediction of drug interactions with topiramate using a CYP450 inhibition spectrum [abstract]. Epilepsia 1995; 36 Suppl. 4: 47
31. Johannessen SI. Pharmacokinetics and drug interactions: a non-issue for some new antiepileptic drugs? In: Topiramate in Perspective. International Epileptology Symposium: 1995 Nov 11-12: London
32. Bourgeois BF. Drug interaction profile of topiramate. Epilepsia. In press
33. Peters DH, Sorkin EM. Zonisamide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs 1993; 45: 760-87
34. Ito T, Yamaguchi T, Miyazaki H, et al. Pharmacokinetic structure od AD-810, a new antiepileptic compound in phase I trials. Arzneimittel Forschung 1982; 32: 1581-6
35. 14C)-methyl)-1,2-benzisoxazole (AD-810) in rats, dogs, monkeys and of AD-810 in man. Arzneimitteforschung 1983; 33: 961-8
36. Siedlik P, Brockbrader H, Chang T, et al. Effect of food on the oral absorption of zonisamide in normal healthy volunteers [abstract]. Pharm Res 1986; 3 Suppl: S158
37. Seino M, Naruto S, Ito T, et al. Other antiepileptie drugs: zonisamide. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. New York: Raven Press, 1995: 1011-23
38. Taylor CP, McLean JR, Brockbrader HN, et al. Zonisamide (AD-810, C1-912). In: Meldrum BS, Porter RJ, editors. New anticonvulsant drugs. London: John Libbey, 1986: 277-94
39. Hashimoto Y, Odani A, Tanigawara Y, et al. Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients. Biol Pharm Bull 1994; 17: 323-6
40. Matsumoto K, Miyazaki H, Fujii T, et al. Binding of sulfonamides to erythrocytes and their components. Chem Pharm Bull 1989; 37: 1913-5
41. Kimura M, Tanaka N, Kimura Y, et al. Factors influencing serum concentration of zonisamide in epileptic patients. Chem Pharm Bull 1992; 40: 193-5
42. Matsumoto K, Miyazaki H, Fujii T, et al. Binding of sulfonamides to erythrocyte proteins and possible drug-drug interaction. Chem Pharm Bull 1984; 37: 2807-10
43. Nishiguchi K, Ohnishi N, Iwakawa S, et al. Pharmacokinetics of zonisamide: saturable distribution into human and rat erythrocytes and into rat brain. J Pharmacobiodyn 1992; 15: 409-15
44. Ojemann LM, McLean JR, Buchanan RA. Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. Ther Drug Monit 1986; 8: 293-6
45. Sackellares JC, Donofrio PD, Wagner JG, et al. Pilot study of zonisamide (1,2-benzisoxazole-3-methanesulfonamide) in patients with refractory partial seizures. Epilepsia 1985; 26: 206-11
46. 14C-zonisamide in rats, dogs and monkeys. Xenobiot Metab Disp 1989; 4: 11-8
47. 14C-zonisamide in healthy volunteers [abstract]. Pharm Res 1986; 3 Suppl.: 159s
48. Nakasa H, Komiya M, Ohmori S, et al. Characterization of human liver microsomal cytochrome P450 involved in the reductive metabolism of zonisamide. Mol Pharmacol 1993; 44: 218-21
49. Wagner JG, Sackellares JC, Donofrio PD, et al. Nonlinear pharmacokinetics of CI-912 in adult epileptic patients. Ther Drug Monit 1984; 6: 277-83
50. Wilensky AJ, Friel PN, Ojemann LM, et al. Zonisamide in epilepsy: a pilot study. Epilepsia 1985; 26: 212-20
51. Shimizu A, Yarnamoto J, Yamada Y, et al. The antiepileptic effect of zonisamide in patients with refractory seizures. Curr Ther Res 1987; 42: 147-55
52. Ono T, Yagi K, Seino M. Clinical efficacy and safety of a new antiepileptic drug, zonisamide: a multi-institutional phase III study. Seishin Iyaku 1988; 30: 471-82
53. Fukushima K, Yagi K, Seino M, et al. Phase II study of zonisamide (ZNA), a new antiepileptic drug, in epileptic children. Jpn J Pediatr 1987; 40: 3389-97
54. Yagi K, Seino M, Mihara, T, et al. Open clinical trial of new antiepileptic drug, zonisamide (ZNA) on 49 patients with refractory epileptic seizures. Clin Psych 1987; 29: 111-9
55. Kaku M, Ishitsu T, Chikazawa S, et al. Serum concentrations of zonisamide in children with epilepsy. J Kyushu Pharm Soc 1991; 45: 2-30
56. Yagi K, Seino M. Methodological requirements for clinical trials in refractory epilepsies: our experience with zonisamide. Proceedings of the Symposium on Advances in Basic Research and Treatment of Refractory Epilepsy; 1990 Sep 10-14: Kyoto. Tokyo: Dainippon Pharm Co Ltd. 1990: 16-9
57. Schentag JJ, Gengo FM, Wilton JH, et al. Influence of phenobarbital, cimetidine, and renal disease on zonisamide kinetics [abstract]. Pharm Res 1987; 4 Suppl.: S79
58. Naito H, Itoh N, Matsui N, et al. Monitoring plasma concentrations of zonisamide and clonazepam in an epileptic attempting suicide by an overdose of the drugs. Curr Ther Res 1988; 43: 463-7
59. Oguni H, Hayakawa T, Fukuyama Y. Clinical trial of zonisamide, a new antiepileptic drug, in cases of refractory childhood epilepsy. J Jpn Epilep Soc 1989; 7: 43-50
60. Shuto H, Sugimoto T, Yasuhara A, et al. Efficacy of zonisamide in children with refractory partial seizures. Curr Ther Res 1989; 45; 1031-6
61. Imuma K, Handa I, Fueki N, et al. Effects of zonisamide (AD-810) on refractory epilepsy in children: special reference to temporal lobe abnormalities. Curr Ther Res 1988; 43: 281-90
62. Kanazawa O, Kanemoto K, Sengoku A, et al. A clinical trial of zonisamide on adults and children with refractory epilepsy: thirty-five cases with a long administration for more than one year J Jpn Epil Soc 1990; 8: 29-38
63. Sakamoto K, Kurokawa T, Tomita N, et al. Effects of zonisamide in children with epilepsy. Curr Ther Res 1988; 43: 378-83
64. Abo J, Miura H, Takanashi S, et al. Drug interaction between zonisamide and carbamazepine: a pharmacokinetic study in children with cryptogenic localization-related epilepsies [abstract]. Epilepsia 1995; 36 Suppl. 3: S162
65. Kaneko S, Hayashimoto A, Niwayaim H, et al. Effects of zonisamide on serum levels of phenytoin and carbamazepine. Jpn J Epil Soc 1993; 11: 31-5
66. Browne TR, Szabo GK, Kres J, et al. Drug interactions of zonisamide (CI-912) with phenytoin and carbamazepine. J Clin Pharmacol 1986; 26: 555
67. Minami T, Ieiri I, Ohtsuho K, et al. Influence of additional therapy with zonisamide (Excegran) on protein binding and metabolism of carbamazepine. Epilepsia 1994; 35: 1023-5
68. Suzdak PD, Jansen JA. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 1995; 36: 612-26
69. Lassen LC, Sommerville K, Mengel HB, et al. Summary of five controlled trials with tiagabine as adjunctive treatment of patients with partial seizures [abstract]. Epilepsia 1995; 36 Suppl. 3: S148
70. Gustavson L, Mengel H. Pharmacokinetics of tiagabine, a gamma-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses. Epilepsia 1995; 36: 605-11
71. Inami M, Watanabe H, Tajahashi A, et al. Tiagabine in healthy Japanese subjects: single- and multiple-dose study [abstract]. Epilepsia 1995; 36 Suppl. 3: S158
72. Jansen JA, Oliver S, Dirach J, et al. Absolute bioavailability of tiagabine [abstract]. Epilepsia 1995; 36 Suppl. 3: S159
73. Brodie M. Pharmacology - tiagabine in profile. In: Tiagabine: the art of epilepsy care. Proceedings of a Satellite Symposium to the 21st International Epilepsy Congress; 1995 Sep 2: Syndey. Sydney: Novo Nordisk, 1995: 8-12
74. Leppik IE, So E, Pask CA, et al. Pharmacokinetic study of tiagabine HCl in patients at multiple steady-state dose [abstract]. Epilepsia 1993; 34 Suppl. 6: 355
75. 14C)-tiagabine HCl after oral administration to human subjects [abstract]. Epilepsia 1995; 36 Suppl. 3: S158
76. 14C)-tiagabine by human hepatic microsomes [abstract]. Epilepsia 1995; 36 Suppl. 3: S159
77. Mengel HB, Pierce MW, Mant TGB, et al. Tiagabine: safety and tolerance during 2-week multiple dosing to healthy volunteers [abstract]. Epilepsia 1991; 32 Suppl. 1: 99-100
78. Snel S, Mukherjee S, Richens A, et al. Pharmacokinetics of tiagabine in the elderly [abstract]. Epilepsia 1993; 34 Suppl. 2: 157
79. Cato A, Qian JX, Gustavson LE, et al. Pharmacokinetics and safely of tiagabine in subjects with various degrees of renal function [abstract]. Epilepsia 1995; 36 Suppl. 3: S159
80. Gustavson LE, Qian JX, Saulis R, et al. Pharmacokinetics and safety of tiagabine in subjects with varying degrees ot hepatic function [abstract]. Epilepsia 1995; 36 Suppl. 3: S159
81. Richens A, Gustavson LE, McKelvy JF, et al. Pharmacokinetics and safety of single-dose tiagabine HCl in epileptic patients chronically treated with four other antiepileptic drug regimens [abstract]. Epilepsia 1991; 32 Suppl. 1: 12
82. Ostergaard LH, Gram L, Dam M. Potential antiepileptic drugs: tiagabine. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. New York: Raven Press, 1995: 1057-61
83. Gustavson LE, Cato A, Guenther HJR, et al. Lack of clinically important drug interactions between tiagabine and carbamazepine, phenytoin, or valproate [abstract]. Epilepsia 1995; 36 Suppl. 3: S159
84. Mengel H, Janson JA, Sommerville K, et al. Tiagabine: evaluation of the risk of interaction wilh theophylline, warfarin, digoxin, cimetidine, oral contraceptives, triazolam, or ethanol. Epilepsia 1995; 36 Suppl. 3: S160
85. Mengel HB, Houston A, Back DJ. An evaluation of the interaction between tiagabine and oral contraceptives in female volunteers. J Pharm Med 1994; 4: 141-50
86. Stables J, Bialer M, Johannessen SI, et al. Progress report on new antiepileptic drugs: a summary of the Second Eilat Conference. Epilepsy Res 1995; 22: 235-46
87. Bebin M, Black TP. New anticonvulsant drugs: focus on flunarizine, fosphenytoin, midazolam and stiripentol. Drugs 1994; 48: 153-71
88. Donn KH, Drissel DA, Quon CY. Systemic availability and pharmacokinetics of phenytoin after intramuscular ACC-9653, a phenytoin prodrug [abstract]. Epilepsia 1987; 28: S87
89. Boucher BA, Bombassaro AM, Rasmussen SN, et al. Phenytoin prodrug 3-fosphoryloxymethylphenytoin (ACC-9653: pharmacokinetics in patients following intravenous and intramuscular administration. J Pharm Sci 1989; 78: 429-32
90. Browne TR, Davoudi H, Donn KH, et al. Bioavailability of ACC-9653 (phenytoin prodrug). Epilepsia 1989; 30 Suppl. 2: S27-32
91. Leppik IE, Boucher BA, Wilder BJ, et al. Pharmacokinetics and safety of a phenytoin prodrug given IV and IM in patients. Neurology 1990; 40: 456-60
92. Gerber N, Mays DC, Dohn KH, et al. Safety, tolerance and pharmacokinetics of intravenous doses of the phosphate ester of 3-hydroxymethyl-5,5-diphenylhydantoin, a new prodrug of phenytoin. J Clin Pharmacol 1988; 28: 1023-32
93. Fischer PA, Sloan EP, Turnbull TL, et al. Safety and pharmacokinetics of intravenous loading doses of fosphenytoin for acute treatment of seizures. Epilepsia 1995; 36 Suppl. 3: S160
94. Leppik IE, Boucher BA, Wilder BJ, et al. Phenytoin prodrug: preclinical and clinical studies [abstract]. Epilepsia 1989; 30 Suppl. 2: S22-6
95. Cower AJ, Noyer M, Verloes R, et al. ucb LO59, A novel anti-convulsant drug: pharmacological profile in animals. Eur J Pharmacol 1992; 222: 193-203
96. Patsalos PN, Walker MC, Ratnaraj N, et al. The pharmacokinetics of levetiracelam (UCB LO59) in patients with intractable epilepsy [abstract]. Epilepsia 1995; 36 Suppl. 4: 54
97. Edelbroeck PM, de Wilde-Ockeleon JM, Kaslelejin-Nolste-Trenite DGA, et al. Evaluation of the pharmacokinetics and neuropsychometrics parameters in chronic comedicated epileptic patients of three increasing dosages of a novel antiepileptic drug, ucb LO59 250 mg capsules per each dose for one week followed by two weeks of placebo [abstract]. Epilepsia 1993; 34 Suppl. 2: 7
98. Stein U. Potential antiepileptic dugs: losigamone. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. New York: Raven Press, 1995: 1025-34
99. Kramer G, Wad N, Bredel-Geissler A, et al. Losigamone-phenytoin interaction: a placebo-controlled, double-blind study in healthy volunteers. Epilepsia 1995; 36 Suppl. 3: S63
100. Kramer G, Wad N, Bredel-Geissler A, et al. Losigamone-valproate interaction: a placebo-controlled, double-blind study in healthy volunteers [abstract]. Epilepsia 1995; 36 Suppl. 4: 53
101. Palmer GC, Clark B, Hutchinson JB. Antiepileptic and neuro-protective potential of remacemide hydrochloride. Drugs Future 1993; 18: 1021-42
102. Palmer GC, Murray RJ, Wilson TCM, et al. Biological profile of the metabolites and potential metaboliles of the anticonvulsant remacemide. Arch Intern Pharmacodyn Ther 1992; 317: 16-34
103. Clark B, Hutchison JB, Jamieson V, et al. Potential antiepileptic dugs: losigamone. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepilcptic drugs. New York: Raven Press, 1995; 1035-44
104. Scheyer RD, Cramer JA, Leppik IE, et al. Remacemide elimination after initial and chronic dosing [abstract]. Clin Pharmacol Ther 1992; 51: 89
105. Leach JP, Blacklaw J, Stewart M, et al. Mutual pharmacokinetic interactions between remacemide hydrochloride and carbamazepine [abstract]. Epilepsia 1995; 36 Suppl. 3: S163
106. Levy RH, Lin HS, Blehart H, et al. Pharmacokinetics of stiripentol in normal man: evidence of nonlinearity. J Clin Pharmacol 1983; 23: 523-33
107. Loiseau P, Duche B. Potential antiepileptic drugs: stiripentol. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. New York: Raven Press, 1995: 1045-56
108. Levy RH, Loiseau P, Guyot M, et al. Michaelis-Menten kinetics of stiripentol in normal humans. Epilepsia 1984; 25: 486-91
109. Levy RH, Loiseau P, Guyot M, et al. Effects of stiripentol on valproate plasma level and metabolism [abstract]. Epilepsia 1987; 28: 605
110. Levy RH, Loiseau P, Guyot M, et al. Stiripentol kinetics in epilepsy: nonlinearity and interactions. Clin Pharmacol Ther 1984; 36: 661-9
111. Farwell JR, Anderson GD, Kerr B, et al. Stiripentol in atypical absence seizures in children: an open trial. Epilepsia 1993; 34: 305-11
112. Moreland TA, Astoin J, Lepage F, et al. The metabolic fate of stiripentol in man. Drug Metab Dispos 1986; 14: 654-62
113. Mather GG, Bishop FE, Trager WF, et al. Mechanisms of stiripentol interactions with carbamazepine and phenytoin [abstract]. Epilepsia 1995; 36 Suppl. 3: S162
114. Kerr BM, Martinez-Lage JM, Viteri C, et al. Carhamazepine dose requirements during stiripentol therapy: influence of cytochrome P450 inhibition by stiripentol. Epilepsia 1991; 32: 267-74
115. Levy RH, Martinez-Lage M, Kerr BM, et al. Effect of stiripentol on the formation and elimination of carbamazepine epoxide [abstract no. 71]. 17th International Epilepsy Congress; 1987 Sep 6-11: Jerusalem.
116. Loiseau P, Tor J. Stiripentol in absence seizures [abstract]. Epilepsia 1987; 28: 579
117. Loiseau P, Strube E, Tor J, et al. Evaluation neuropsychologique et thérapeutique du stiripentol dans l'epilepsie: resultats préliminaires. Rev Neurol 1988; 144: 165-72
118. Levy RH, Loiseau P, Guyot M, et al. Effects of stiripentol on valproate plasma level and metabolism [abstract]. Epilepsia 1987; 28: 605
119. Levy RH, Loiseau P, Guyot M, et al. Effect of stiripentol dose on valproate metabolism [abstract]. Epilepsia 1988; 29: 709
120. Levy RH, Rettenmeier AW, Anderson GD, et al. Effects of polytherapy with phenytoin. carbamazepine and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clin Pharmacol Ther 1990; 48: 725-35